BioPartnering North America Continues to Grow
SOQUEL, Calif. — BioPartnering North America:
Success of Technology Vision Group’s Global BioPartnering Series Attracts a Growing International Audience
Hosted by BC Biotech, BioAlberta, and BIOTECanada, the 3rd Annual BioPartnering North America conference (BPN, www.techvision.com/bpn/) will take place in Vancouver, B.C., Canada at the Westin Bayshore Resort & Marina on February 6-8, 2005. Commenting on BPN, Barry Gee, Director, Operations and Communications, BC Biotech said, “In its short history, BPN has already established itself as one of the most valuable partnering events in the world. We’re incredibly proud to host the conference here in British Columbia, and look forward to once again welcoming the international biotechnology community to our province.”
BPN is the sister conference to the highly successful BioPartnering Europe (BPE) conference held in London, which entered its 12th year this past October. Produced by Technology Vision Group LLC (TVG), these two key annual BioPartnering meetings offer companies a focused business development experience that is consistently excellent, efficient, and cost-effective. Together, BPE and BPN will continue to build relationships among innovative companies from around the world.
Dr. Robert Lee Kilpatrick, Partner at TVG, commented on the success of TVG’s BioPartnering event, “With clients in 40 countries, we are familiar with the world’s leading centers of bioscience leadership. Without a doubt, British Columbia offers a strong foundation of academic excellence, combined with two of North America’s most successful bioscience companies – QLT and Angiotech – and a strong commitment to the future growth and development of this sector. We are pleased that BioPartnering North America was launched in B.C. and continues to make a contribution to the success of this key industry in the province. We are delighted to be a part of this dynamic community and have created a new BioPartnering North America Student Bursary to assist talented young people to support their education in the bioscience field.”
BPN 2005 will feature all the hallmarks of previous events with the Open House Presentations, Emerging Company Presentations, BioPartnering Leadership Series, Sponsor Workshops and numerous networking opportunities.
The Open House Presentations will feature 56 biopharmaceutical and diagnostics companies, who will give interactive presentations in specially constructed booths. Business development executives are available during a 2-hour period for informal discussions with delegates. Presenters are encouraged to devise unique ways to showcase aspects of their businesses including: science and technology; partnering strategies; developmental programs; commercialization plans; product opportunities; and manufacturing capabilities. The Open House format is a hybrid style that incorporates the presentation of detailed information found in podium presentations, with the feel of a business development meeting.
Avidex, a UK biotech that has participated in both BPE and BPN in the past, will be one of the 2005 Open House Presenters. Dr. Neill MacKenzie, Chief Business Officer at Avidex, commented, “BPN offers an intimate and exclusive venue that attracts major North American pharma and biotechs who want to cut proper product or platform related deals. On top of that, it’s a beautiful venue and close to Whistler so I always pack my snowboard!”
Sixteen young companies will be chosen to give short presentations in the main plenary hall as part of the Emerging Company Presentation sessions. These presentations are a traditional element of the BioPartnering conference programs. In the past, BPN and BPE have featured many young companies that have gone on to become some of the industry’s most important players.
Companies interested in either the Open House or Emerging Company presentations are invited to apply for these sessions, as soon as possible, via the BPN website – www.techvision.com/bpn/.
BPN continues to attract top decision makers from pharmaceutical and biotech companies worldwide. Pharmaceutical companies from Japan, Europe, the U.S. and Canada will be represented at this year’s event. So far this year, the number of pharmaceutical companies attending BPN 2005 is up over last year’s attendance by 30% and continues to grow.
Pharmaceutical companies signed on to attend BPN 2005 thus far include: 3M Healthcare Ltd., ALK-Abello A/S, Angiotech Pharmaceuticals, Inc., AstraZeneca, BioWa, Inc.,Boehringer-Ingelheim GmbH, Bristol-Myers Squibb, CoTherix, ICOS Corporation, Japan Tobacco Pharma, Menarini Group, Merck & Co., Inc., Merck Frosst Canada Ltd., Novartis Corporation, Nycomed Pharma, Pfizer, Procter & Gamble Pharmaceuticals, QLT Inc., Roche, Tanabe Seiyaku Co., Ltd., and Wyeth Pharmaceuticals.
Full conference details for this year’s BPN are available online at www.techvision.com/bpn/.
Technology Vision Group LLC
BC Biotech, BIOTECanada, BioAlberta
AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myer Squibb Company, Burrill & Company, Cooley Godward LLP, Dorsey & Whitney LLP, Farris, Genome British Columbia, Gowlings, Innovation and Science Council of British Columbia, Leading Edge British Columbia, Merck, Morrison & Foerster, Novartis, Pfizer, PricewaterhouseCoopers LLP, QLT Inc., RBC Financial Group, Roche, Seed I.P. Law Group PLLC, Simon Fraser University, UK Science & Technology Network, University-Industry Liason Office UBC, Vancouver Economic Development Commission, and Western Economic Diversification Canada.
Biotechnology Focus, BioWorld Today, CCNMatthews, Contact Canada(R), De Facto Communications plc, International Trade Canada, and U.S. Commercial Service.
COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group